Kane Biotech Announces New Private Placement Offering
Rhea-AI Summary
Kane Biotech (OTC:KNBIF) announced a non‑brokered private placement to issue up to 16 million common shares at $0.05 per share for gross proceeds of up to $800,000. Proceeds are intended for working capital and general corporate purposes. Certain insiders may participate. Closing is expected on or about December 17, 2025. All issued shares will be subject to a four‑month and one‑day hold period. The Offering is subject to necessary approvals, including the TSX Venture Exchange. Securities will not be registered in the United States and may not be offered or sold in the U.S. or to U.S. persons.
Positive
- Raises up to $800,000 to bolster liquidity
- Proceeds designated for working capital and general corporate purposes
- Four‑month and one‑day hold limits immediate resale
Negative
- Issuance of up to 16 million shares may dilute existing shareholders
- Insiders may participate, potentially increasing insider ownership concentration
- Closing and funding subject to TSX Venture Exchange approval
Not for distribution to U.S. news wire services or dissemination in the United States
WINNIPEG, Manitoba, Nov. 27, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces its intention to undertake a non-brokered private placement offering (the “Offering”) of up to 16 million common shares (“Shares”) at a price of
The net proceeds of the Offering will be used for working capital and general corporate purposes. Certain insiders of Kane Biotech may participate in the Offering. Closing of the Offering is expected to take place on or about December 17, 2025.
All Shares issued in connection with the Offering are subject to a hold period of four-months and one day from the date of issuance.
The Offering is subject to receipt of all necessary approvals, including the approval of the TSX Venture Exchange.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall it constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale is unlawful. These securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States or to U.S. persons unless registered or exempt therefrom.
About Kane Biotech Inc. (TSX-V: KNE)
Kane Biotech is developing novel wound care treatments that disrupt biofilms and transform healing outcomes. Biofilms are one of the main contributors to antibiotic resistance in wounds which results in serious clinical outcomes and significant cost. revyve® addresses both biofilms and wound bacteria. revyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Gel Spray are US FDA 510(k) cleared. revyve® Antimicrobial Wound Gel is Health Canada approved. To learn more about revyve, visit revyvegel.com or revyvegel.ca.
Join Kane’s Distribution List & Social Media:
To stay informed on the latest developments, sign-up for the Company’s email distribution list HERE.
Follow Kane
Website: kanebiotech.com
LinkedIn: https://www.linkedin.com/company/kanebiotech/
Presentations: https://kanebiotech.com/publications-posters/
| For more information: | |
| Dr. Robert Huizinga | Ray Dupuis |
| Interim CEO | Chief Financial Officer |
| Kane Biotech Inc. | Kane Biotech Inc. |
| rhuizinga@kanebiotech.com | rdupuis@kanebiotech.com |
| (780) 970-1100 | (204) 298-2200 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedarplus.ca. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
FAQ
What is Kane Biotech's private placement size and price (KNBIF)?
When is the expected closing date for Kane Biotech's Offering (KNBIF)?
How will Kane Biotech use the funds from the private placement (KNBIF)?
Will shares from Kane Biotech's private placement be immediately tradable (KNBIF)?
Can U.S. investors participate in Kane Biotech's private placement (KNBIF)?
Does Kane Biotech require regulatory approval for the private placement (KNBIF)?
